Monitoring Adverse Events Following Immunization With a New Conjugate Vaccine Against Group A Meningococcus in Niger, September 2010
In Niger, the introduction campaign of MenAfriVac™, a new conjugate vaccine against Neisseria meningitidis serogroup A, was conducted in the District of Filingue, during September 2010. The authors of this article, published in Vaccine, set up an enhanced surveillance system to monitor adverse events following immunization (AEFI) during the campaign period and after. Although the results are limited by underreporting of cases, the authors did not identify safety concerns with MenAfriVac™. The lessons learned from this experience should be used to reinforce the national pharmacovigilance system in Niger to make it complaint with international standards. In order to do so, the authors recommend using a lighter system for routine; and conducting regular training and supervisory activities to increase its acceptance among local health workers. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Chaibou MS, Bako H, Salisou L, et al.
Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Chaibou MS, Bako H, Salisou L, et al. Monitoring Adverse Events Following Immunization With a New Conjugate Vaccine Against Group A Meningococcus in Niger, September 2010. Vaccine. 2012;30(35):5229–5234.